Dexmedetomidine as an Adjuvant to Local Anesthesia in Quadratus Lumborum Block After Cesarean Delivery
Study Details
Study Description
Brief Summary
Postoperative pain is considered one of the major problems after abdominal operations, so proper pain control is one of the main issues in clinical practice. Cesarean section (CS.) is one of the most common abdominal surgeries and the use of CS. worldwide has increased to unprecedented levels. Effective postoperative analgesia enhances early recovery of the delivered mother, early ambulation, breast feeding and decreases the risk of postoperative thromboembolism. Therefore, Opioids are prescribed routinely for postoperative pain control, but they have many adverse effects such as nausea, vomiting, constipation, excessive sedation, dizziness, respiratory depression, and addiction, so it is important to practice alternative opioid sparing analgesic approaches. Recently, QL block is considered one of the perioperative pain management techniques used in patients undergoing various pelvi-abdominal surgeries. Quadratus Lumborum block inhibits both pain components (somatic and visceral) as a result of local anesthetic spread to the paravertebral spaceA study has been published comparing the analgesic efficacy between QLB and TAP block after cesarean section and proved that QL block II is more effective than TAP Block regarding pain relief and duration of action after CS. Also, Many studies have been published and prove that Combination of adjuvants like (fentanyl, clonidine and MgSo4,etc.) to local anesthetics agents helps in prolonging the analgesic effect and decrease 24hours opiate consumption.one of these adjuvants which used extensively in the regional techniques is dexmedetomidine, which is a selective alpha-2 adrenergic agonist. The optimal dosage of dexmedetomidine to be added to local anesthetics still remains unclear, but in other studies the dose of 0.5 μg/kg is widely used with no postoperative complications.
in this double blinded randomized controlled trial, the investigators compare the analgesic efficacy of adding dexmedetomidine to local anesthetic in quadratus lumborum block and their role in reduction postoperative opioid consumption after cesarean section
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Using a computer-generated randomization schedule, fifty patients will be randomly assigned into two equal groups: group A (bupivacaine only; n=25) and group B (bupivacaine plus dexmedetomidine; n=25).
All participants, investigators, care providers and outcome assessors will be blinded to the study group allocation.
The day Prior to surgery, all patients will have pre anesthesia check-up with routine and subjective investigations and explained about the Numerical Rating Scale (NRS) ranging from 0-10 (0 indicating no pain and 10 for severe intractable pain) The patients will be pre medicated by 40mg oral pantoprazole at night and in the morning of the surgery.
On arrival to the operating room, patients will be monitored by peripheral pulse oximetry, five-lead electrocardiogram and non-invasive blood pressure monitor. Two 18-gauge intravenous cannulae will be inserted in the nondominant arm and 1500 ml crystalloid will be infused as acoload plus ephedrine infusion 4mg/min. to prevent post spinal hypotension.
Random allocation of patients into one of two groups using concealed closed envelope method, the patients' envelope which contain the number of group will be opened and recorded in the data collection sheet as a number of group because the data collector will be blinded to the intervention on the patient, only the anesthetist knows each number is referring to which intervention.
Spinal anesthesia will be performed with the patient in the sitting position at the level of L2 to 3 or L3 to 4 intervertebral spaces using a 25-gauge Quincke Bevel type needle (Spinocan®, Braun Melsungen AG,Germany) with 10 mg of hyperbaric bupivacaine(AstraZeneca Pharmaceuticals, UK) and 25μ g of fentanyl. Patients will be placed in the supine position with left uterine displacement and a face-mask will be applied to deliver oxygen at rate of 6 L/minute.
Five minutes after spinal injection, Spinal anesthesia level will be assessed by loss of cold (ice cube) and touch (blunt pin) discrimination and will be considered successful if a bilateral sensory blockade to T4-T6 is established. Anesthesia and surgical management will be performed in the usual manner.
At the end of surgery, all patients will receive 1 gm of intravenous paracetamol. After the abdomen will be cleaned with surgical solution, covering the wound and while the patient is still fully monitored, the patient will be placed in the lateral decubitus position and the QLB will be performed.
A convex (5-8 MHz) ultrasound probe (Shenzhen Mindray BIO-Medical Electronics, Model: DP-20, China) with a protective sheath will be used after imaging depth and gain is adjusted. The procedure will be done under complete aseptic condition (facemask, gown, and gloves) after cleaning of the abdominal skin with antiseptic solution.
The probe will be placed in the mid axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall (transversus abdominis, internal oblique, and external oblique). Then, scan dorsally keeping the transverse orientation until observing that the transversus abdominus muscle became aponeurotic, and this aponeurosis will be followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle , followed by recognition of Shamrock pattern by viewing psoas major muscle (PM) anteriorly, the erector spinae muscle (ESM) posteriorly and the QL muscle adherent to the apex of the transverse process (trifoliate).
Stimuplex® A 21G 100-mm needle (B. BRAUN, Melsungen AG, Germany) will be inserted in plane under real time US guidance from anterolateral to posteromedial direction via the abdominal wall. Two milliliters of 0.9% saline will be injected to visualize the solution spread (hydro dissection) to determine the optimal point of injection over the lumbar interfacial triangle.
Group A will be injected with 20 ml of 0. 25% bupivacaine in each side. (14) Group B will be injected with 20 ml of 0. 25% bupivacaine in each side added to it dexmedetomidine 0.5 μg/kg; (Precedex 100 μg/ml (Hospira, inc, lake forest, USA).
Patients will be transferred to the post anesthesia care unit (PACU) and discharged from PACU when fully conscious, hemodynamically stable and pain free.
All patients will receive IV paracetamol 1gm every 8 hours. As a rescue analgesic, IV morphine (0.05 mg/kg) will be given when Numerical Rating Scale (NRS) > 3, maximum dose of morphine will be given 30 mg per day.
the following data will be recorded:
-
Total morphine consumption at predetermined time intervals (4, 8, 12, and 24) hrs. after surgery
-
Numerical Rating Scale (NRS) ranging from 0-10 (0 indicating no pain and 10 for severe intractable pain) will be recorded and compared at 4,8,12, and 24h after surgery.
-
Incidence of post-operative complications as nausea, vomiting or abdominal distension will also be recorded.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: group A (bupivacaine only) Group A will be injected with 20 ml of 0. 25% bupivacaine in each side |
Drug: Bupivacaine 0.25% Injectable Solution
a local anesthetic drug
Other Names:
|
| Active Comparator: group B (bupivacaine plus dexmedetomidine) Group B will be injected with 20 ml of 0. 25% bupivacaine in each side added to it dexmedetomidine 0.5 μg/kg; (Precedex 100 μg/ml (Hospira, inc, lake forest, USA). |
Drug: bupivacaine plus dexmedetomidine
bupivacaine is a local anesthetic drug plus dexmedetomidine is a new generation highly selective α2-adrenergic receptor (α2-AR) agonist that is associated with sedative and analgesic sparing effects
Other Names:
|
Outcome Measures
Primary Outcome Measures
- total amount of morphine consumption [up to 24 hours]
Measure the total amount of morphine consumption at predetermined time intervals (4, 8, 12, and 24) hrs. after surgery
Secondary Outcome Measures
- Numerical Rating Scale [up to 24 hours]
Numerical Rating Scale at rest (static), and on movement (dynamic) at 4, 8, 12, and 24 hours postoperatively. it requires the patient to rate their pain on a defined scale from 0 to 10 where 0 is no pain and 10 is the worst pain imaginable
Other Outcome Measures
- ambulation postoperatively [up to 24 hours]
Time to first Ambulation postoperatively
- quadratus lumborum block complications [up to 24 hours]
Quadratus lumborum Block related complications e.g. bowel injury, hematoma formation, nerve injury and intravascular injection.
- sedation score [up to 24 hours]
Sedation scores (Ramsay scale), itching (0, none; 1, mild; 2, moderate; and 3, severe), nausea (0, none; 1, mild;2, moderate; and 3, severe or vomiting), and other complications postoperatively
- Postoperative side effects related to dexmedetomidine [up to 24 hours]
Postoperative side effects related to dexmedetomidine e.g. bradycardia and hypotension.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients scheduled for cesarean section under spinal anesthesia.
-
Normal uncomplicated pregnancies (ASA II).
-
BMI 18.5 to 34.9 kg/m2
Exclusion Criteria:
-
Patient refusal.
-
ASA III - IV patients.
-
Coagulation disorders.
-
Skin lesions or infection at site of proposed needle.
-
Known allergy to any of study drugs.
-
inability to comprehend or use the verbal rating pain scoring system
-
Difficulty in Ultrasonographic identification.
-
Opioid abuse.
-
BMI > 35 Kg/m2.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Faculty of Medicine Cairo University | Cairo | Egypt | 11956 | |
| 2 | Faculty of Medicine | Cairo | Egypt | 11956 |
Sponsors and Collaborators
- Cairo University
Investigators
- Study Director: Nesrine M. El-Refai, professor, Cairo University
Study Documents (Full-Text)
None provided.More Information
Publications
- MD-75-2020